Literature DB >> 16283064

Costs and quality of life associated with osteoporosis-related fractures in Sweden.

Fredrik Borgström1, Niklas Zethraeus, Olof Johnell, Lars Lidgren, Sari Ponzer, Olle Svensson, Peter Abdon, Ewald Ornstein, Karl Lunsjö, Karl Göran Thorngren, Ingemar Sernbo, Clas Rehnberg, Bengt Jönsson.   

Abstract

This prospective observational data collection study assessed the cost and quality of life related to hip, vertebral and wrist fracture 1 year after the fracture, based on a patient sample consisting of 635 male and female patients surviving a year after fracture. Data regarding resource use and quality of life related to fractures was collected by questionnaires at baseline, 4 months and 12 months. Information was collected by the use of patients' records, register sources and by asking the patient. Quality of life was estimated with the EQ-5D questionnaire. Costs were estimated from a societal perspective, including direct and indirect costs. The mean fracture-related cost the year after a hip, vertebral and wrist fracture were estimated, in euros (<euro>), at <euro>14,221, <euro>12,544 and <euro>2,147, respectively [converted from Swedish krona (SEK) at an exchange rate of 9.1268 SEK/<euro>]. The mean reduction in quality of life was estimated at 0.17, 0.26 and 0.06 for hip, vertebral and wrist fracture, respectively. Based on the results, the yearly burden of osteoporosis in Sweden could be estimated at <euro>0.5 billion (SEK 4.6 billion). The patient sample for vertebral fracture was fairly small and included a high proportion of fractures leading to hospitalization, but they indicate a higher cost and loss of quality of life related to vertebral fracture than previously perceived.

Entities:  

Mesh:

Year:  2005        PMID: 16283064     DOI: 10.1007/s00198-005-0015-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  35 in total

1.  Health-related quality of life of Colles' fracture patients.

Authors:  P Dolan; D Torgerson; T K Kakarlapudi
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

2.  Swedish population health-related quality of life results using the EQ-5D.

Authors:  K Burström; M Johannesson; F Diderichsen
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

3.  Quality of life related to fear of falling and hip fracture in older women: a time trade off study.

Authors:  G Salkeld; I D Cameron; R G Cumming; S Easter; J Seymour; S E Kurrle; S Quine
Journal:  BMJ       Date:  2000-02-05

Review 4.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

5.  Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.

Authors:  Fredrik Borgström; Olof Johnell; John A Kanis; Anders Oden; David Sykes; Bengt Jönsson
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 6.  Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.

Authors:  A H Briggs; D E Wonderling; C Z Mooney
Journal:  Health Econ       Date:  1997 Jul-Aug       Impact factor: 3.046

7.  Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease.

Authors:  M Janzon; L A Levin; E Swahn
Journal:  Eur Heart J       Date:  2002-01       Impact factor: 29.983

8.  The cost of a hip fracture. Estimates for 1,709 patients in Sweden.

Authors:  N Zethraeus; L Strömberg; B Jönsson; O Svensson; G Ohlén
Journal:  Acta Orthop Scand       Date:  1997-02

9.  Excess mortality after hospitalisation for vertebral fracture.

Authors:  John A Kanis; Anders Oden; Olof Johnell; Chris De Laet; Bengt Jonsson
Journal:  Osteoporos Int       Date:  2003-11-04       Impact factor: 4.507

10.  Estimating the costs of hip fracture and potential savings.

Authors:  N Zethraeus; U G Gerdtham
Journal:  Int J Technol Assess Health Care       Date:  1998       Impact factor: 2.188

View more
  125 in total

1.  Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.

Authors:  F Borgström; O Ström; M Kleman; E McCloskey; H Johansson; A Odén; J A Kanis
Journal:  Osteoporos Int       Date:  2010-06-08       Impact factor: 4.507

2.  A novel sheep vertebral bone defect model for injectable bioactive vertebral augmentation materials.

Authors:  X S Zhu; Z M Zhang; H Q Mao; D C Geng; J Zou; G L Wang; Z G Zhang; J H Wang; L Chen; H L Yang
Journal:  J Mater Sci Mater Med       Date:  2010-12-03       Impact factor: 3.896

3.  Responsiveness of the Short Musculoskeletal Function Assessment (SMFA) in patients with femoral neck fractures.

Authors:  Carl Johan Hedbeck; Jan Tidermark; Sari Ponzer; Richard Blomfeldt; Gunnar Bergström
Journal:  Qual Life Res       Date:  2010-11-12       Impact factor: 4.147

4.  Gene-modified adult stem cells regenerate vertebral bone defect in a rat model.

Authors:  Dmitriy Sheyn; Ilan Kallai; Wafa Tawackoli; Doron Cohn Yakubovich; Anthony Oh; Susan Su; Xiaoyu Da; Amir Lavi; Nadav Kimelman-Bleich; Yoram Zilberman; Ning Li; Hyun Bae; Zulma Gazit; Gadi Pelled; Dan Gazit
Journal:  Mol Pharm       Date:  2011-09-13       Impact factor: 4.939

5.  Lavage prior to vertebral augmentation reduces the risk for cement leakage.

Authors:  Sven Hoppe; Tarek Elfiky; Marius Johann Baptist Keel; Emin Aghayev; Timo Michael Ecker; Lorin Michael Benneker
Journal:  Eur Spine J       Date:  2015-08-15       Impact factor: 3.134

6.  Pain and fracture-related limitations persist 6 months after a fragility fracture.

Authors:  Joanna E M Sale; Lucy Frankel; Stephen Thielke; Larry Funnell
Journal:  Rheumatol Int       Date:  2017-06-20       Impact factor: 2.631

7.  Hospitalised osteoporotic vertebral fractures in Spain: analysis of the national hospital discharge registry.

Authors:  C Bouza; T López; M Palma; J M Amate
Journal:  Osteoporos Int       Date:  2007-01-13       Impact factor: 4.507

8.  Prevalence of osteoporosis in men aged 65-75 in a primary care setting. A practice audit after application of the Canadian 2010 guidelines for osteoporosis screening.

Authors:  Robert Ferrari
Journal:  Clin Rheumatol       Date:  2014-04-30       Impact factor: 2.980

9.  Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Authors:  O Ström; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2012-12-07       Impact factor: 4.507

10.  [Kyphoplasty : method for minimally invasive treatment of painful vertebral fractures].

Authors:  C Kasperk; G Nöldge; P Meeder; P Nawroth; F X Huber
Journal:  Chirurg       Date:  2008-10       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.